A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

Pharmacia & Upjohn

Status and phase: Completed; Phase 2

Conditions: HIV Infections

Treatments: Drug: Delavirdine mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002210

228D

0069

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.

Sex: All

Ages: 1 month to 15 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV infection.
• Plasma HIV-1 levels greater than 10,000 copies/ml.